Plain-English translation of NCT07667751 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three drugs—sunitinib, olaparib, and tislelizumab—given before surgery to women with advanced ovarian cancer that has specific genetic markers. The goal is to shrink tumors as much as possible before the surgical team removes them, and then continue treatment afterward to help prevent the cancer from coming back.
Current standard treatments before ovarian cancer surgery only help about half of patients achieve complete tumor removal, which increases the risk of cancer returning. Researchers believe adding this medication combination to standard approaches might help more patients have their tumors completely removed and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive three medications by mouth and infusion over about 9 weeks before surgery to shrink your tumor. After the surgical team removes as much cancer as possible, you would continue treatment with six cycles of additional chemotherapy followed by maintenance therapy for up to one year. Throughout this time, you would have regular blood tests, imaging scans, and clinic visits to monitor your response and manage any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China